Baltera Robert Jr. 4

What Happened Robert Baltera Jr., a director of Palisade Bio, acquired a total of 50,000 common shares in two open-market purchases: 20,000 shares on 2026-07-06 and 30,000 shares on 2026-07-07. The filing reports weighted-average prices of $2.05 (20,000 shares, ~$41,040) and $2.03 (30,000 shares, ~$61,044), for a combined cash outlay of approximately $102,084. These were purchases (transaction code P), which are purchases of company stock rather than sales or option exercises.

Key Details

• Transaction dates and reported weighted-average prices:
  • 2026-07-06 — 20,000 shares @ $2.05 reported (total ~$41,040). Footnote F1: actual prices in the lot ranged $2.04–$2.068.
  • 2026-07-07 — 30,000 shares @ $2.03 reported (total ~$61,044). Footnote F2: actual prices in the lot ranged $2.00–$2.07.
• Total acquired: 50,000 shares; total reported value ≈ $102,084.
• Shares owned after the transaction: not specified in the provided filing summary.
• Filing date: Form 4 filed 2026-07-08 — appears timely (filed within normal SEC reporting window).
• No 10b5-1 plan, option exercise, gift, or tax-withholding notation indicated in the summary.

Context

• Open-market purchases are direct buys of company stock and are often watched by investors as a potential positive signal, though filings do not state the purchaser’s motive.
• Footnotes note that reported prices are weighted averages across multiple trades; the reporter can provide a breakdown of shares at each individual price upon request.